Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28024977 | 0.98 | CYP3A4 (0.38) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL20091630 | 0.98 | CYP3A4 (0.40) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL11679532 | 0.91 | CYP3A4 (0.33) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14966049 | 0.90 | CYP3A4 (0.43) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL11661164 | 0.89 | CYP3A4 (0.35) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL11679024 | 0.80 | CYP3A4 (0.39) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL11570649 | 0.79 | SIGMAR1 (0.48) | SLC6A3TSHRALDH1A1SIGMAR1HPGD | |
| SCHEMBL20091551 | 0.79 | LMNA (0.48) | CYP2C9CYP2C19TSHRALDH1A1GAA | |
| SCHEMBL6901641 | 0.78 | KCNH2 (0.41) | CYP3A4TDP1CYP2C9CYP2C19KCNH2 | |
| SCHEMBL16775636 | 0.78 | SIGMAR1 (0.47) | SLC6A3TSHRALDH1A1SIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818606-B | Preparation method of ezetimibe and intermediate thereof | 上海博志研新药物技术有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-110818606-A | Preparation method of ezetimibe and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-4003746-A | Organic heterocyclic and thioaryl phosphines in silver halide emulsions and developers therefor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-18 | — | — | US | claimed |
| CN-118005619-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-05-10 | — | — | CN | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110753689-B | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2022-07-05 | — | — | US | disclosed |
| CN-113981020-A | Method for synthesizing lobeline hydrochloride intermediate by enzymatic chiral reduction | 江苏恒盛药业有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-110818606-B | Preparation method of ezetimibe and intermediate thereof | 上海博志研新药物技术有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3760607-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | Takasago International Corporation (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
| EP-1725548-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005090334-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1278737-A2 | PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS | Vertex Pharmaceuticals Incorporated (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081330-A2 | PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | NEK4, TENT4A, TCF4 | CYP3A4 142/4885TDP1 4580/4885CYP2C9 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.